BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
Authors
Keywords
-
Journal
Cancer Medicine
Volume 2, Issue 6, Pages 826-835
Publisher
Wiley
Online
2013-10-31
DOI
10.1002/cam4.146
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DNMT3A mutations at R882 hotspot are only found in major clones of acute myeloid leukemia
- (2013) Kathrin E. Bisling et al. LEUKEMIA & LYMPHOMA
- Phospho Switch Triggers Brd4 Chromatin Binding and Activator Recruitment for Gene-Specific Targeting
- (2013) Shwu-Yuan Wu et al. MOLECULAR CELL
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
- (2012) Panagis Filippakopoulos et al. CELL
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes
- (2011) Katherine Ververis et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- A Small Molecule Binding to the Coactivator CREB-Binding Protein Blocks Apoptosis in Cardiomyocytes
- (2011) Jagat C. Borah et al. CHEMISTRY & BIOLOGY
- Low frequency of DNMT3A mutations in pediatric AML and the identification of the OCI-AML3 cell line as an in vitro model
- (2011) I H I M Hollink et al. LEUKEMIA
- Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia
- (2011) E McCormack et al. LEUKEMIA
- The NPM1 wild-type OCI-AML2 and the NPM1-mutated OCI-AML3 cell lines carry DNMT3A mutations
- (2011) E Tiacci et al. LEUKEMIA
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
- (2011) Johannes Zuber et al. NATURE
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
- (2011) Mark A. Dawson et al. NATURE
- Targeting MYC dependence in cancer by inhibiting BET bromodomains
- (2011) J. A. Mertz et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The impact of acetylation and deacetylation on the p53 pathway
- (2011) Christopher L. Brooks et al. Protein & Cell
- New insights into p53 activation
- (2010) Christopher L Brooks et al. CELL RESEARCH
- The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma
- (2010) Helen J. Stewart et al. EXPERIMENTAL HEMATOLOGY
- Suppression of inflammation by a synthetic histone mimic
- (2010) Edwige Nicodeme et al. NATURE
- BRD7 is a candidate tumour suppressor gene required for p53 function
- (2010) Jarno Drost et al. NATURE CELL BIOLOGY
- A minority of foci or pan-nuclear apoptotic staining of H2AX in the S phase after UV damage contain DNA double-strand breaks
- (2010) S. de Feraudy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes
- (2009) T. J. Gaymes et al. HAEMATOLOGICA
- H2AX Is Required for Cell Cycle Arrest via the p53/p21 Pathway
- (2009) M. Fragkos et al. MOLECULAR AND CELLULAR BIOLOGY
- Acetylation Is Indispensable for p53 Activation
- (2008) Yi Tang et al. CELL
- Brd4 Coactivates Transcriptional Activation of NF- B via Specific Binding to Acetylated RelA
- (2008) B. Huang et al. MOLECULAR AND CELLULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started